NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides 2025 Annual Shareholders Meeting and Company Overview
TL;DR
NanoViricides' broad-spectrum antiviral platform offers investors potential first-mover advantage in treating multiple viral diseases through its novel nanoviricide technology.
NanoViricides develops antiviral drugs using nanoviricide technology licensed from TheraCour, with NV-387 advancing to Phase II trials for respiratory viruses and MPOX.
NanoViricides' antiviral platform could significantly improve global health by providing effective treatments for numerous viral diseases affecting millions worldwide.
NanoViricides is developing drugs against over a dozen viruses using special nanomaterials that trap viruses like tiny nets to prevent infection.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides, Inc. has announced that its 2025 Annual Shareholders Meeting will be held at 10 a.m. on Saturday, November 8, 2025, at the Hampton Inn & Suites in Stamford, Connecticut.
NanoViricides is a publicly traded clinical-stage company (NYSE American: NNVC) that develops broad-spectrum antiviral drugs using special purpose nanomaterials called nanoviricides.
The lead drug candidate is NV-387, a broad-spectrum antiviral drug planned for development as a treatment for RSV, COVID, Long COVID, Influenza, other respiratory viral infections, and MPOX/Smallpox infections.
NV-HHV-1 is mentioned as an advanced drug candidate for the treatment of Shingles.
The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The nanoviricide technology is based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc., with NanoViricides holding exclusive licenses for specific antiviral applications.
The company is developing drugs against oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, Ebola virus, and others.
The company states that drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development or become successful products.
The full press release can be viewed at https://ibn.fm/7IcXQ, and more company information is available at www.nanoviricides.com.
Curated from InvestorBrandNetwork (IBN)
